Hosted on MSN23h
GSK lowered to hold by Jefferies, valuation disconnect citedJefferies lowered GSK (NYSE:GSK) to hold, citing a valuation disconnect between fundamentals and price. Jefferies said it ...
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...
We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...
Health Canada has granted approval for GlaxoSmithKline’s ( GSK) Ojjaara (momelotinib) for treating myelofibrosis (MF) in ...
Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm finds it “frustrating” that despite the favorable Zantac settlement, robust ...
The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...
Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...
GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback